切换至 "中华医学电子期刊资源库"
高级检索
中华普通外科学文献(电子版)

中华普通外科学文献(电子版) ›› 2022, Vol. 16 ›› Issue (02) : 141 -145. doi: 10.3877/cma.j.issn.1674-0793.2022.02.012

综述

肝细胞癌肺转移的治疗现状
卢潼辉1, 徐锋1,†()   
  1. 1. 110004　沈阳，中国医科大学附属盛京医院普通外科
  • 收稿日期:2022-02-19 出版日期:2022-04-01
  • 通信作者: 徐锋
  • 基金资助:
    辽宁省自然科学基金项目(20180551193，2020-MS-181); 盛京医院345人才工程计划资助项目(40B)

Current status of the treatment of hepatocellular carcinoma with pulmonary metastasis

Tonghui Lu1, Feng Xu1,†()   

  1. 1. Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang 110004, China
  • Received:2022-02-19 Published:2022-04-01
  • Corresponding author: Feng Xu
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

卢潼辉, 徐锋. 肝细胞癌肺转移的治疗现状[J]. 中华普通外科学文献(电子版), 2022, 16(02): 141-145.

Tonghui Lu, Feng Xu. Current status of the treatment of hepatocellular carcinoma with pulmonary metastasis[J]. Chinese Archives of General Surgery(Electronic Edition), 2022, 16(02): 141-145.

肝细胞癌（简称"肝癌"）是我国第2位肿瘤致死病因，肝外转移是其预后不良的重要原因。随着影像学技术的不断进步，肝癌合并肝外转移的发现率逐年上升，其中肺是最常见的肝外转移器官。肝癌肺转移患者情况复杂，处理起来十分棘手，治疗方式尚无定论，各类指南仅建议行系统治疗，但收效甚微。本文归纳总结了肝癌肺转移的各种治疗手段和研究现状，以期为患者提供最佳个体化的综合治疗策略，从而提高其生存获益。

关键词: 肝细胞癌, 肺转移瘤, 治疗, 综述

Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death in China, and extrahepatic metastasis is an important reason for its poor prognosis. With the continuous progress of imaging technology, the detection rate of HCC with extrahepatic metastasis is increasing year by year, among which the lung is the most common extrahepatic metastatic organ. The situation of HCC patients with lung metastasis is complex, which is very difficult to deal with and the treatment mode is still inconclusive. All kinds of guidelines only recommend systematic treatment, but with little effect. In this paper, various treatments for lung metastasis of HCC are summarized in order to provide the best individualized comprehensive treatment strategy for patients, so as to improve their survival benefits.

Key words: Hepatocellular carcinoma, Pulmonary metastasis, Treatment, Review
[1]
Zheng R, Zhang S, Zeng H, et al. Cancer incidence and mortality in China, 2016[J]. JNCC, 2022, 2(1): 1-9.
[2]
Wu W, He X, Andayani D, et al. Pattern of distant extrahepatic metastases in primary liver cancer: A SEER based study[J]. J Cancer, 2017, 8(12): 2312-2318.
[3]
Wu C, Ren X, Zhang Q. Incidence, risk factors, and prognosis in patients with primary hepatocellular carcinoma and lung metastasis: A population-based study[J]. Cancer Manag Res, 2019, 11: 2759-2768.
[4]
Hu Z, Li W, Huang P, et al. Therapeutic significance and indications of pulmonary metastasectomy for hepatocellular carcinoma following liver resection[J]. Int J Surg, 2017, 48: 23-31.
[5]
Lee HP, Yun JK, Jung HS, et al. Surgical outcomes of pulmonary metastasectomy in hepatocellular carcinoma patients according to approach method: thoracoscopic versus open approach[J]. World J Surg Oncol, 2021, 19(1): 33.
[6]
Mizuguchi S, Nishiyama N, Izumi N, et al. Clinical significance of multiple pulmonary metastasectomy for hepatocellular carcinoma[J]. World J Surg, 2016, 40(2): 380-387.
[7]
Kuo TM, Chang KM, Cheng TI, et al. Clinical factors predicting better survival outcome for pulmonary metastasectomy of hepatocellular carcinoma[J]. Liver Cancer, 2017, 6(4): 297-306.
[8]
叶欣，范卫君，王徽, 等. 热消融治疗原发性和转移性肺部肿瘤专家共识（2017年版）[J]. 中国肺癌杂志, 2017, 20(7): 433-445.
[9]
葛夕洪，刘祥，蔡金贞, 等. 肝癌肝移植术后肺寡转移瘤的微波消融治疗效果分析[J/CD]. 实用器官移植电子杂志, 2020, 8(5): 349-352.
[10]
Yuan Z, Liu B, Hu C, et al. Clinical outcomes of percutaneous thermal ablation for pulmonary metastases from hepatocellular carcinoma: A retrospective study[J]. Int J Hyperthermia, 2020, 37(1): 651-659.
[11]
Zuo T, Lin W, Liu F, et al. Artificial pneumothorax improves radiofrequency ablation of pulmonary metastases of hepatocellular carcinoma close to mediastinum[J]. BMC Cancer, 2021, 21(1): 505.
[12]
Hori A, Ohira R, Nakamura T, et al. Transarterial chemoembolization for pulmonary or mediastinal metastases from hepatocellular carcinoma[J]. Br J Radiol, 2020, 93(1110): 20190407.
[13]
李科，孔轶. 进口碘化油TACE联合洛铂治疗晚期肝癌肺转移的临床疗效观察[J]. 实用癌症杂志, 2018, 33(2): 244-246.
[14]
Wang Z, Kong QT, Li J, et al. Clinical outcomes of cyberknife stereotactic radiosurgery for lung metastases[J]. J Thorac Dis, 2015, 7(3): 407-412.
[15]
Zhang F, Wang J, Guo J, et al. Chinese Expert Consensus Workshop Report: Guideline for permanent iodine-125 seed implantation of primary and metastatic lung tumors[J]. Thorac Cancer, 2019, 10(2): 388-394.
[16]
Zhang L, Chen LH, Wang J, et al. CT-guided radioactive 125I seed implantation treatment of multiple pulmonary metastases of hepatocellular carcinoma[J]. Clin Radiol, 2014, 69(6): 624-629.
[17]
Soliman H, Ringash J, Jiang H, et al. Phase Ⅱ trial of palliative radiotherapy for hepatocellular carcinoma and liver metastases[J]. J Clin Oncol, 2013, 31(31): 3980-3986.
[18]
Pelizzaro F, Sammarco A, Dadduzio V, et al. Capecitabine in advanced hepatocellular carcinoma: A multicenter experience[J]. Dig Liver Dis, 2019, 51(12): 1713-1719.
[19]
Qin S, Bai Y, Lim HY, et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia[J]. J Clin Oncol, 2013, 31(28): 3501-3508.
[20]
Hasegawa H, Kawakubo E, Kitagawa D, et al. Combined modality therapy for giant hepatocellular carcinoma and multiple lung metastases-a case study[J]. Gan To Kagaku Ryoho, 2020, 47(13): 2251-2253.
[21]
Shi J, Sun J, Liu C, et al. All-trans-retinoic acid (ATRA) plus oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX) versus FOLFOX alone as palliative chemotherapy in patients with advanced hepatocellular carcinoma and extrahepatic metastasis: study protocol for a randomized controlled trial[J]. Trials, 2019, 20(1): 245.
[22]
Mao X, Tey SK, Yeung C, et al. Nidogen 1-enriched extracellular vesicles facilitate extrahepatic metastasis of liver cancer by activating pulmonary fibroblasts to secrete tumor necrosis factor receptor 1[J]. Adv Sci(Weinh), 2020, 7(21): 2002157.
[23]
Yoshida M, Yamashita T, Okada H, et al. Sorafenib suppresses extrahepatic metastasis de novo in hepatocellular carcinoma through inhibition of mesenchymal cancer stem cells characterized by the expression of CD90[J]. Sci Rep, 2017, 7(1): 11292.
[24]
冯跃，郑家平，邵国良. 索拉非尼治疗肝细胞癌肺转移39例预后分析[J]. 肿瘤学杂志, 2018, 24(10): 987-991.
[25]
Yang T, Lu JH, Lin C, et al. Concomitant lung metastasis in patients with advanced hepatocellular carcinoma[J]. World J Gastroenterol, 2012, 18(20): 2533-2539.
[26]
Chen J, Lu S, Zhang Y, et al. Sorafenib monotherapy versus sorafenib combined with regional therapies for hepatocellular carcinoma patients with pulmonary oligometastases: A propensity score-matched analysis[J]. J Cancer, 2018, 9(10): 1745-1753.
[27]
Li ZJ, Dai HQ, Huang XW, et al. Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma[J]. Acta Pharmacol Sin, 2021, 42(2): 301-310.
[28]
Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial[J]. Lancet, 2018, 391(10126): 1163-1173.
[29]
Lee MJ, Chang SW, Kim JH, et al. Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: A multicenter retrospective study in Korea[J]. Invest New Drugs, 2021, 39(1): 260-268.
[30]
Du X, Chen D, Lin Z, et al. Efficacy of apatinib in advanced hepatocellular carcinoma with lung metastasis: A retrospective, multicenter study[J]. J BUON, 2019, 24(5): 1956-1963.
[31]
Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): A randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2019, 20(2): 282-296.
[32]
El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088): 2492-2502.
[33]
Kudo M, Matilla A, Santoro A, et al. CheckMate 040 cohort 5: A phase Ⅰ/Ⅱ study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis[J]. J Hepatol, 2021, 75(3): 600-609.
[34]
Yau T, Park JW, Finn RS, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): A randomised, multicentre, open-label, phase 3 trial[J]. Lancet Oncol, 2022, 23(1): 77-90.
[35]
Kim CG, Kim C, Yoon SE, et al. Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma[J]. J Hepatol, 2021, 74(2): 350-359.
[36]
Yau T, Kang YK, Kim TY, et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial[J]. JAMA Oncol, 2020, 6(11): e204564.
[37]
Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020, 382(20): 1894-1905.
[38]
Ren Z, Xu J, Bai Y, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): A randomised, open-label, phase 2-3 study[J]. Lancet Oncol, 2021, 22(7): 977-990.
[39]
Xu J, Shen J, Gu S, et al. Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): A nonrandomized, open-label, phase Ⅱ trial[J]. Clin Cancer Res, 2021, 27(4): 1003-1011.
[1] 李淼, 朱连华, 韩鹏, 姜波, 费翔. 高帧频超声造影评价肝细胞癌血管形态与风险因素的研究[J]. 中华医学超声杂志（电子版）, 2023, 20(09): 911-915.
[2] 丁建民, 秦正义, 张翔, 周燕, 周洪雨, 王彦冬, 经翔. 超声造影与普美显磁共振成像对具有高危因素的≤3 cm肝结节进行LI-RADS分类诊断的前瞻性研究[J]. 中华医学超声杂志（电子版）, 2023, 20(09): 930-938.
[3] 江泽莹, 王安婷, 王姣丽, 陈慈, 周秋玲, 黄燕娟, 周芳, 薛琰, 周剑烽, 谭文勇, 杜美芳. 多种植物油组分预防肿瘤放化疗相关毒性反应的效果分析[J]. 中华损伤与修复杂志(电子版), 2023, 18(06): 523-527.
[4] 朴广昊, 李屹洲, 刘瑞, 赵建民, 王凌峰. 皮肤撕脱伤撕脱皮瓣活力早期评估与修复的研究进展[J]. 中华损伤与修复杂志(电子版), 2023, 18(06): 528-532.
[5] 董杰, 杨松, 杨浩, 陈翔, 张万里. 乙酰辅酶A羧化酶2基因高甲基化与肝细胞癌临床病理因素和生存期的关系[J]. 中华普通外科学文献(电子版), 2023, 17(06): 433-437.
[6] 王得晨, 杨康, 杨自杰, 归明彬, 屈莲平, 张小凤, 高峰. 结直肠癌微卫星稳定状态和程序性死亡、吲哚胺2,3-双加氧酶关系的研究进展[J]. 中华普通外科学文献(电子版), 2023, 17(06): 462-465.
[7] 彭旭, 邵永孚, 李铎, 邹瑞, 邢贞明. 结肠肝曲癌的诊断和外科治疗[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 108-110.
[8] 马伟强, 马斌林, 吴中语, 张莹. microRNA在三阴性乳腺癌进展中发挥的作用[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 111-114.
[9] 孔博, 张璟, 吕珂. 超声技术在复杂腹壁疝诊治中的作用[J]. 中华疝和腹壁外科杂志(电子版), 2023, 17(06): 670-673.
[10] 陆志峰, 周佳佳, 梁舒. 虚拟现实技术在治疗弱视中的临床应用研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(08): 891-895.
[11] 李田, 徐洪, 刘和亮. 尘肺病的相关研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(08): 900-905.
[12] 岳瑞雪, 孔令欣, 郝鑫, 杨进强, 韩猛, 崔国忠, 王建军, 张志生, 孔凡庭, 张维, 何文博, 李现桥, 周新平, 徐东宏, 胡崇珠. 乳腺癌HER2蛋白表达水平预测新辅助治疗疗效的真实世界研究[J]. 中华临床医师杂志(电子版), 2023, 17(07): 765-770.
[13] 符梅沙, 周玉华, 李慧, 薛春颜. 淋巴细胞免疫治疗对复发性流产患者外周血T淋巴细胞亚群分布与PD1/PD-L1表达的影响及意义[J]. 中华临床医师杂志(电子版), 2023, 17(06): 726-730.
[14] 李变, 王莉娜, 桑田, 李珊, 杜雪燕, 李春华, 张兴云, 管巧, 王颖, 冯琪, 蒙景雯. 亚低温技术治疗缺氧缺血性脑病新生儿的临床分析[J]. 中华临床医师杂志(电子版), 2023, 17(06): 639-643.
[15] 戴俊, 李硕, 曹影, 汪守峰, 宋红毛, 蔡菁菁, 邵敏, 陈莉, 程雷, 怀德. 鼻内镜下改良高选择性翼管神经低温等离子消融术对中重度变应性鼻炎的效果研究[J]. 中华临床医师杂志(电子版), 2023, 17(06): 689-693.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号